2023 World Conference on Lung Cancer (Posters)-EP12.01. Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure

EP12.01. Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to analyze the clinical efficacy of aumolertinib dosing modifications with combination therapy for patients with refractory leptomeningeal metastasis (LM) after osimertinib failure. Nine patients who experienced osimertinib failure were included in the study, and they underwent rechallenge with a doubled dosage of aumolertinib in combination with bevacizumab. Additionally, all patients received intraventricular pemetrexed. The primary endpoint was progression-free survival (PFS), and secondary endpoints included cranial enhanced magnetic resonance imaging (MRI) scans and cerebrospinal fluid (CSF) CEA levels. The results showed that the median PFS was 11 months and the median overall survival (OS) was 14 months. Subgroup analysis revealed that patients with concurrent TP53 mutation had a median PFS of 7 months. One patient achieved a sustained clinical response for 15 months. MRI scans showed a significant reduction in LM lesions in 6 patients and complete disappearance in 3 patients. The average CSF CEA levels decreased after 2 months of therapy. The study concluded that aumolertinib rechallenge strategies, such as doubling the dosage combined with intraventricular chemotherapy, with or without bevacizumab, may improve clinical outcomes for EGFR-mutant NSCLC patients with refractory LM after osimertinib failure. This combination regimen has a rapid onset of action and a long duration of remission.

Asset Subtitle

Shencun Fang

Meta Tag

Speaker Shencun Fang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

clinical efficacy

aumolertinib dosing modifications

combination therapy

refractory leptomeningeal metastasis

osimertinib failure

rechallenge

doubled dosage

intraventricular pemetrexed

progression-free survival

EGFR-mutant NSCLC